Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab, NALIRIFOX, and SBRT for Conversion Therapy in Locally Advanced Pancreatic Cancer
NCT07827053Phase 2Not yet recruiting
- Sponsor
- Shanghai General Hospital
- Start
- Sep 2026
- Primary completion
- Sep 2029
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Shanghai General Hospital. Primary endpoint: Surgical conversion rate at 3 years. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07827053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07827053.